Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...
Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise ...